Phylogica Announces Successful In Vivo Results - Peptide Vaccine T-cell Expansion | Finance News Network

Media ReleasesPhylogica

View All Phylogica News


Phylogica Announces Successful In Vivo Results - Peptide Vaccine T-cell Expansion

PYC is pleased to announce successful in vivo results in the evaluation of its peptide vaccine program.

Highlights:

- PYC’s Cell Penetrating Peptides (CPPs) elicit a substantially stronger CD8+ T cell expansion than the ‘gold standard’ CPP ‘TAT’ in vivo;

- Phylogica’s CPPs triggered an antigen-specific immune response similar in magnitude to that raised against a Herpes Simplex Virus (HSV) infection (an indication of the strength of T cell response to be expected from a healthy mouse in response to a strong viral stimulus);

- In a complementary experiment, the T-cells generated in response to the vaccination had the ability to kill cells expressing the receptor that they are created to recognise (target cells); and

- In combination, the experiments demonstrate the efficacy of the CPP-antigen conjugate in stimulating a CD8+ T cell immune response that is capable of recognising and killing the target cell.


For further information please download PDF attached:
Download this document